Celyad SA (CYAD)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
Pre-market:
| Previous close | 3.6900 |
| Open | 3.6500 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 2900 |
| Day's range | 3.3800 - 3.7000 |
| 52-week range | 3.3800 - 8.4380 |
| Volume | |
| Avg. volume | 1,004,211 |
| Market cap | 81.456M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3410 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.47 |
- Zacks
Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?
Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.
- Business Wire
Celyad Oncology Provides Outlook for 2022
MONT-SAINT-GUIBERT, Belgium, January 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review and provided an outlook for 2022.
- Zacks
5 Beaten-Down Biotech Bets to Bounce Back in 2022
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
© 2022 Yahoo. All rights reserved.
